Evaluation of the Effectiveness of Curcumin and Piperine co-supplementation on Inflammatory factors, Cardiac biomarkers, Atrial fibrillation, and Clinical outcomes after Coronary Artery Bypass Graft Surgery

Background Coronary artery bypass graft (CABG) is one of the preferred treatments for patients with heart problems, especially in individuals with other comorbidities and when multiple arteries are narrowed. This study aimed to assess the effects of administrating curcumin-piperine on patients who underwent CABG surgery. Methods This was a randomized, double-blind, placebo-controlled clinical trial, in which 80 eligible adults who underwent CABG surgery, were randomized into 4 groups. Patients received 3 tablets daily for 5 days after the surgery, which contained curcumin-piperine (each tablet contained 500 mg curcumin + 5 mg piperine) or a placebo (each tablet contained 505 mg maltodextrin). Group A received 3 placebo tablets, group B received 2 placebos and one curcumin-piperine tablet, group C received 1 placebo and 2 curcumin-piperine tablets, and group D received 3 curcumin-piperine tablets. Before and after the intervention, C-reactive protein (CRP), total antioxidant capacity (TAC), cardiometabolic factors, clinical outcomes, and 28-day mortality were evaluated. Results Between-group analysis showed that CRP significantly decreased (P=0.028), and TAC significantly increased (P=0.033) after the intervention (Post hoc analysis showed that for CRP, the difference was between group B and D, and for TAC was between group C and D). Between-group analysis also showed that creatine kinase mono-phosphate (CK-MB) marginally reduced (P=0.077); however, changes for troponin I (P=0.692), lactate dehydrogenase (LDH) (P=0.668), ejection fraction (P=0.340), and arterial fibrillation (P=0.99) were not significant. Blood urea nitrogen (P=0.820) and serum creatinine (P=0.244) did not show notable changes between groups. Conclusion Supplementation with curcumin-piperine had a promising effect on serum CRP and TAC. It also had a favorable impact on CK-MB among patients who underwent CABG surgery. Trial registration IRCT20201129049534N4, available on https://en.irct.ir/trial/56930.